DOVER, DE — December 17, 2025 — Leads & Copy — AlphaTON Capital Corp (NASDAQ: ATON) plans to launch a decentralized, AI-native biotech platform focused on rare and immune-suppressed cancers, starting with mesothelioma.
The planned platform is designed as a privacy-first decentralized-AI network for rare cancers that can learn across institutions without centralizing patient-sensitive data. In its initial phase, AlphaTON expects the platform to deliver outputs for mesothelioma, including biomarker and responder insights, enrichment strategies, and trial design simulations to inform clinical trials at Cyncado Therapeutics, a wholly owned subsidiary of AlphaTON, alongside prioritization of repurposing candidates and novel combinations. Over time, the platform is intended to evolve into a continuous engine for therapeutic discovery and development, progressing toward new drug design.
AlphaTON, the technology company scaling the Telegram super app, with an addressable market of 1 billion monthly active users, plans to expand the training base through additional proprietary datasets from partners, subject to permissions and governance. The platform will be trained initially on proprietary oncology datasets and program learnings from Cyncado Therapeutics, providing a foundation in rare-cancer model development.
The initiative will be advanced through a dedicated platform entity that will seek independent third-party financing and non-dilutive funding at the platform level, while AlphaTON’s role will focus on infrastructure enablement, governance, and strategic alignment. The company expects the platform to bring together privacy-first, multi-institution learning, a discovery engine for therapies, responder intelligence, rare-cancer trial playbooks and at-scale infrastructure using Telegram distribution, TON rails for identity, consent, contribution credentials, and Cocoon compute.
Participation in multi-institution collaborations is expected to be subject to institutional approvals, patient consent where applicable, and compliance with privacy and data protection laws. AlphaTON expects to build a Telegram-native scientific collaboration layer designed to accelerate participation and learning in rare cancers. This may include TON-based, non-transferable contribution credentials to recognize verified scientific contributions including dataset curation and annotation, model validation, protocol simulation, biomarker review, and hypothesis generation.
Cyncado Therapeutics owns TT-4, TT-10, and related IP and datasets generated across its programs. AlphaTON anticipates that the platform entity will enter into a multi-year data and R&D agreement with Cyncado to license and curate relevant datasets and support translational and correlative work tied to AI-generated hypotheses. Cyncado is expected to remain the IND holder and clinical sponsor for its programs.
Over the next approximately 12 months, AlphaTON expects to establish the dedicated platform entity and governance, finalize initial data and R&D agreements, and launch an initial platform release anchored on Cyncado datasets plus selected external cohorts. The Company expects this first phase to produce outputs for mesothelioma, including prioritized repurposing and combination hypotheses, biomarker and enrichment insights, and trial design simulations to inform upcoming clinical plans. In parallel, AlphaTON expects to initiate multi-institution pilot collaborations and launch the Telegram-native scientific collaboration layer, including contribution credentials and workflows to accelerate dataset curation, annotation, and model validation.
As the platform matures, AlphaTON expects to evaluate a structured approach to advancing individual assets, including the potential to in-license or acquire rights to therapies into dedicated SPVs with program-specific financing to support clinical trials under governance and ring-fenced budgets, while also using platform-generated insights to inform the design of new drugs over time.
AlphaTON Capital CEO Brittany Kaiser said that rare cancers have science, but the data is scattered and the patient numbers are small. She stated that privacy-first decentralized-AI can help institutions and sponsors learn faster together, without forcing sensitive patient data into one place. Cyncado Therapeutics CEO Peter Molloy said that Cyncado brings proprietary datasets and program learnings in mesothelioma and other settings that can seed this platform from day one. He stated that their intent is to keep Cyncado as a biotech while enabling a network to translate multi-institution learning into therapeutic advances.
Investor Relations:
AlphaTON Capital Corp
AlphaTON@icrinc.com
(203) 682-8200
Media Inquiries:
Richard Laermer
RLM PR
AlphaTON@rlmpr.com
(212) 741-5106 X 216
Richard Laermer RLM PR AlphaTON (at) rlmpr.com
Source: AlphaTON Capital
